RespiDerm Corporation has received Notice of Allowance from the European Patent Office for its mobile device called AirJector®!
Little Rock, AR—June. 13, 2017—RespiDerm®, the pioneer in noninvasive transdermal delivery of medical gases for chronic conditions, announces that it has been granted a Notice of Allowance by the European Patent and Trademark Office (EPO) for MOBILE APPARATUS FOR THE DISPERSION AND TRANSDERMAL DELIVERY OF PHARMACEUTICAL, MEDICAL, OR PURIFIED CARBON DIOXIDE GAS. This notice is of EP patent 16708.0001EPWO, which now protects an apparatus and therapeutic treatment called AirJector® that was developed for chronic conditions using medical gases applied by transdermally and noninvasively, its functionality, and other criteria.
This technological development allows RespiDerm® to be the first to enable wide application of medical gases to be applicable in various health care environments and for self-care users. Treatment with these medical gases has been shown to help prevent and treat chronic conditions caused by lack of circulation in microcapillaries, including peripheral arterial disease, extremity ischemia, and diabetic wounds. With this know-how, we can assist millions of patients around the world to access cost-effective and easy-to-use treatments, while providing economic benefits to treatment providers at the same time.
“Some of the many benefits the AirJector® medical device offers is that the treatment is safe and noninvasive, it applies naturally available and FDA-approved medical gases for the fraction of the cost compared to other invasive products, measurable results during first treatment, fast healing with reduced recovery time and hospital release, increased quality of life, and that AirJector® is a portable handheld device applicable in virtually any environment by any adult without special training. With this newly deployed capability, we have transcended the industry’s capacity to handle and manage these growing problems cost effectively. This gives our customers the advantage helping patients with chronic conditions while generating continuous income,” said RespiDerm’s Founder and CEO, Tibor Salamon.
The following countries were designated in this European application:
Austria (AT), Belgium (BE), Bulgaria (BG), Croatia (HR), Cyprus (CY), Czech Republic (CZ), Denmark (DK), Estonia (EE), Finland (FI), France (FR), Germany (DE), Greece (GR), Hungary (HU), Iceland (IS), Ireland (IE), Italy (IT), Latvia (LV), Lithuania (LT), Luxembourg (LU), Malta (MT), Monaco (MC), the Netherlands (NL), Norway (NO), Poland (PL), Portugal (PT), Romania (RO), San Marino (SM), Serbia (RS), Slovakia (SK), Slovenia (SI), Spain (ES), Sweden (SE), Switzerland/Liechtenstein (CH), Turkey (TR), and the United Kingdom (GB).
RespiDerm’s intellectual property portfolio now includes issued utility patents in over 30 countries, as well as design patents and many trademarks.